Loading
Alpha-emitting PSMA drugs that produce responses even after Pluvicto fails, held back mainly by isotope supply.
Novartis (225Ac-PSMA-617, phase 3 AcTION), Bayer (225Ac-PSMA-Trillium with albumin binder, PAnTHA phase 1 at ASCO GU 2026), Fusion/AstraZeneca (FPI-2265, 225Ac-PSMA-I&T, phase 3 AlphaBreak), and academic 225Ac-PSMA data from South Africa and Germany. Xerostomia from salivary uptake is dose-limiting.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
PSMA ligand with 225Ac; four alpha emissions per decay chain. Connects to PSMA.
1.Radioligand circulates and binds PSMA on tumour cells
Source: clinicaltrials.gov. Doses are for orientation; the current label governs.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-03-19 | Fusion Pharmaceuticals (AstraZeneca) to AstraZeneca FPI-2265 (actinium-225 PSMA) and the Fusion targeted alpha therapy platform | Acquisition | $2.0bn | up to $2.4bn including a contingent value right | source |
Compare all products across the US, EU, UK, Japan, China and Australia →
AstraZeneca completes Fusion Pharmaceuticals acquisition; FPI-2265 phase 3 planned source
| Adverse event |
|---|
| Xerostomia |
| Anaemia |
| Thrombocytopenia |
| Renal toxicity |
Dose-limiting in academic series. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational (phase 3) | not disclosed | - |
| Germany | Compassionate use at selected centres (Heidelberg and others) | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Actinium-225 PSMA agents" OR ABSTRACT:"Actinium-225 PSMA agents" OR TITLE:"225Ac-PSMA-617" OR ABSTRACT:"225Ac-PSMA-617" OR TITLE:"225Ac-PSMA-I&T" OR ABSTRACT:"225Ac-PSMA-I&T" OR TITLE:"BAY 3563254 Trillium" OR ABSTRACT:"BAY 3563254 Trillium") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Actinium-225 PSMA agents, not a curated reading list.
Shares Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
Shares Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer, Actinium-225 supply: thorium stocks, accelerators and radium targets, PSMA, Metastatic castration-resistant prostate cancer.
Shares Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, Beta radioligand → alpha radioligand, Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmaceutical roadmap: iodine → lutetium → actinium.
Shares Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
Shares PSMA expression by PET (PSMA-positive), PSMA, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.
Shares PSMA expression by PET (PSMA-positive), PSMA, Novartis, Prostate cancer.
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.